• Explore /
  • Poster
  • / Phase I trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and peritoneal carcinomatosis or positive peritoneal cytology.

Phase I trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and peritoneal carcinomatosis or positive peritoneal cytology.

Abstract Poster

Authors

null

Brian D. Badgwell

The University of Texas MD Anderson Cancer Center, Houston, TX

Brian D. Badgwell , Mariela A. Blum-Murphy , Naruhiko Ikoma , Jeannelyn Estrella , Jenny Jing Li , Jitesh D. Kawedia , Paul F. Mansfield , Jaffer A. Ajani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04220827

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 360)

DOI

10.1200/JCO.2024.42.3_suppl.360

Abstract #

360

Poster Bd #

H2

Abstract Disclosures

Similar Posters

First Author: Raghav Sundar

First Author: Brian D. Badgwell

Poster

2024 ASCO Genitourinary Cancers Symposium

Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).

Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).

First Author: Ding-Wei Ye

First Author: Daniel Brungs